Ventral Posteromedial Nucleus is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The ventral posteromedial nucleus (VPM) of the thalamus is a critical relay station for somatosensory information from the head and face. It receives input from the spinal trigeminal nucleus and projects to the primary somatosensory cortex. The VPM is involved in sensory discrimination, pain perception, and is implicated in various neurological disorders including thalamic pain syndrome, multiple sclerosis, and neurodegenerative conditions. [1]
| Property | Value | [2]
|----------|-------| [3]
| Cell Type | Thalamocortical projection neurons, interneurons | [4]
| Brain Region | Thalamus (ventral tier) | [5]
| Primary Function | Craniofacial somatosensation, taste, pain, temperature | [6]
| Key Molecular Markers | VGLUT2, VGLUT3, Calbindin, Parvalbumin | [7]
| Neurotransmitters | Glutamate, GABA |
The VPM is located in the posterolateral thalamus, bounded by:
| Cell Type | Percentage | Function |
|---|---|---|
| Thalamocortical relay neurons | ~70% | Main output to cortex |
| Local interneurons | ~25% | Local processing |
| Dendritic arborizing neurons | ~5% | Intralaminar inputs |
| Marker | Expression | Function |
|---|---|---|
| VGLUT2 | Relay neurons | Glutamate vesicular transport |
| VGLUT3 | Subset of neurons | Modulatory signaling |
| Calbindin D-28k | Interneurons | Calcium buffering |
| Parvalbumin | Fast-spiking neurons | Synchronization |
| CaBP (Calybindin) | Relay neurons | Calcium handling |
| SOM (Somatostatin) | Interneurons | Inhibition |
| Aspect | Mechanism |
|---|---|
| Lesion location | VPM, VPL |
| Onset | Weeks to months post-stroke |
| Features | Contralateral hemibody pain, allodynia |
| Pathophysiology | Loss of inhibitory control, thalamic hyperactivity |
Pharmacological
Neuromodulation
Surgical
Cell-based
Pharmacological
Closed-loop systems
The study of Ventral Posteromedial Nucleus has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lenz et al. Thalamic pain syndrome (2021). 2021. ↩︎
Crunelli & Huguenard, Thalamic oscillations (2020). 2020. ↩︎
Guye et al. Thalamic DBS for pain (2021). 2021. ↩︎
Karnath et al. Thalamic syndrome (2023). 2023. ↩︎